Discontinued — last reported Q4 '20
An increase suggests successful monetization of intellectual property and growth in licensed product commercialization, while a decrease may indicate patent expirations or declining performance of licensed assets.
This metric represents the revenue generated from product sales specifically attributed to the royalty-bearing segment o...
Comparable to licensing revenue or royalty income reported by other biotechnology and pharmaceutical firms that leverage intellectual property to generate passive or semi-passive revenue streams.
amgn_segment_royalty_product_sales